BiotechTube

Growth hormone + Growth hormone treatment and puberty

ApprovedTerminated
0 watching 0 views this week🔥 Hot
85
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
✓
Phase 3
5
Approved
Indication / Disease

Hypothyroidism

Conditions

Hypothyroidism

Trial Timeline

May 1, 2003 → Nov 1, 2011

NCT ID
NCT00206375

About Growth hormone + Growth hormone treatment and puberty

Growth hormone + Growth hormone treatment and puberty is a approved stage product being developed by Eli Lilly for Hypothyroidism. The current trial status is terminated. This product is registered under clinical trial identifier NCT00206375. Target conditions include Hypothyroidism.

Hype Score Breakdown

Clinical
30
Activity
20
Company
10
Novelty
10
Community
12

Clinical Trials (1)

NCT IDPhaseStatus
NCT00206375ApprovedTerminated

Competing Products

5 competing products in Hypothyroidism

See all competitors
ProductCompanyStageHype Score
Armour Thyroid + LevothyroxineAbbViePhase 2/3
65
iodinated contrast agentsBayerPre-clinical
20
Iohexol + Iodixanol + Iopromide + IoversolBayerApproved
82
Iodinated contrast agentsBayerPre-clinical
20
levothyroxine sodiumXeris PharmaceuticalsPhase 2
47

Other Products from Eli Lilly

Insulin Glargine + Insulin Lispro Premix (mid-mixture and low-mixture)Approved
85
Olanzapine + PlaceboApproved
85
exenatide and sitagliptin + exenatide and placeboApproved
85
Tirzepatide + PlaceboApproved
85
tadalafilApproved
85